Close Menu

NEW YORK ─ Boulder, Colorado-based Biodesix on Wednesday announced an agreement with HiberCell to conduct further development of an enzyme-linked immunosorbent assay (ELISA) as a companion diagnostic test.

As part of the agreement, Biodesix will develop a CDx test to select patients for enrollment in HiberCell’s future registrational clinical trials. In an initial program, the ELISA-based CDx will be validated in Biodesix’s New York State CLEP-approved and CLIA-accredited lab.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.